Efficacy of dimethyl fumarate treatment for moderate-to-severe plaque psoriasis: presentation extracts from the 29^th EADV virtual congress, 29-31 October 2020

ABSTRACT

Background: The 29th EADV Virtual Congress took place between the 29th-31st of October 2020. On October 29th, there was a Session on systemic treatment in which Professors Ulrich Mrowietz and Mar Llamas-Velasco presented the latest research on the efficacy of dimethyl fumarate (DMF) treatment for moderate-to-severe plaque psoriasis (BRIDGE and DIMESKIN 1 studies, respectively). The accepted DMF abstract from Professor Matthias Augustin, on the SKILL study, is also presented here. Results: Data from either prospective interventional (BRIDGE) or non-interventional (DIMESKIN 1, SKILL) studies among patients with moderate-to-severe psoriasis showed that DMF provides a positive efficacy profile in all four body regions included in the Psoriasis Area and Severity Index assessment (head and neck, trunk, upper and lower extremities) and a particularly interesting profile (strong efficacy) in the head and neck region. These findings may be of special interest to patients with scalp psoriasis who have been using topical therapies for a long time. Patient-reported outcomes (quality of life, pruritus) also improved during the 24 weeks of DMF treatment. The safety profile of DMF was similar to the previously described with fumaric acid esters. Conclusions: In summary, these results confirm the favorable efficacy and safety profile of DMF in long-term treatment.

KEYWORDS:

• BRIDGE
• dimeskin 1
• dimethyl fumarate
• efficacy
• psoriasis
• skill

Acknowledgments

The authors would like to thank E. Mateu, PhD from TFS S.L., for their writing and editorial assistance.

Reviewer disclosures

A peer reviewer co-authored one of the abstracts included in the manuscript and is collaborating with Almirall. Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Declaration of interest

AK, AR, IP-C, MG, FJF-S, and SD were employees of Almirall; AS served as a statistical consultant for Almirall; CL-J did not have relevant financial disclosure to declare; ED has the following conflict of interests: Advisory Board member, consultant, grants, research support, participation in clinical trials, honorarium for speaking, research support, with the following pharmaceutical companies: AbbVie/Abbott, Almirall, Amgen, Janssen-Cilag, Leo Pharma, Novartis, Pfizer, MSD-Schering-Plough, Celgene, Lilly, and UCB; IH did not have relevant financial disclosure to declare; JMC has participated as a PI/SI and/or invited speaker and/or advisor for Almirall, Gebro, Janssen, Amgen, AbbVie, Leo Pharma, Mylan, Sandoz, Novartis, and Lilly; LS-B has the following conflict of interests: Advisory Board member, consultant, grants, research support, participation in clinical trials, honorarium for speaking, research support, with the following pharmaceutical companies: AbbVie, Almirall, Janssen-Cilag, Leo Pharma, Novartis, Pfizer, MSD-Schering-Plough, Celgene, and Lilly; MA has served as a consultant and/or researcher and/or received research grants from: Abbvie, ALK-Abello, Almirall, Altrazeal, Amgen GmbH, Astellas, Bayer Healthcare, Beiersdorf, Biogen, Birken, Boehringer Ingelheim, BSN, Celgene, Centocor, Coloplast, Flen Pharma, Galderma, Gerromed, GlaxoSmithKline, Heigel.com, Janssen-Cilag, Johnson&Johnson, Leo, Lilly, Medac, Medi, Medovent, Mölnlycke, MSD, Novartis, Pfizer, Pharmafacts, Pohl-Boskamp, Sandoz, Sanofi-Aventis, Söring, Stallergenes, Stiefel, Systagenix Wound Management, Tissue therapies, Urgo, and Xenoport; ML-V has potential conflicts of interests (advisory board member, consultant, research support, participation in clinical trials and honorary for speaking) with the following pharmaceutical companies: AbbVie, Almirall, Amgen, Boehringer, Celgene, Janssen, Leo Pharma, Lilly, Novartis, and UCB, not related with the submitted work; PdlC has been a consultant and advisor and/or received speaking fees and/or grants and/or served as an investigator in clinical trials for the following companies: AbbVie, Almirall, Astellas, Biogen, Boehringer, Celgene, Janssen, Leo Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, and UCB; PvdK received fees for consultancy service or lecturerships from Celgene, Centocor, Allmirall, Amgen, Pfizer, Philips, Abbott, Eli Lilly, Galderma, Novartis, Jansen Pharmaceutica, Leo Pharma, Sandoz, Bristol Mayer Squib, and Dermavant; UM has been an advisor and/or received speaker honoraria and/or received grants and/or participated in clinical trials for Abbott, AbbVie, Almirall Hermal, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Foamix, Forward Pharma, Galderma, Janssen, Leo Pharma, Lilly, Medac, Miltenyi Biotec, MSD, Novartis, Pfizer, Teva, UCB, BBL, and XenoPort. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

This research was funded by Almirall, Barcelona, Spain.